# A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

> **NCT04632056** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 329 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Beovu

## Key facts

- **NCT ID:** NCT04632056
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-16
- **Primary completion:** 2022-11-10
- **Final completion:** 2022-11-10
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04632056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04632056, "A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04632056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*